For tirzepatide (Zepbound) Jastreboff and colleagues reported in the New England Journal of Medicine in 2022 that at maximal doses, the percent of individuals reporting side effects were as follows: Nausea 31.0% Diarrhea 23.0% Vomiting 12.2% Constipation 11.7% Bettge and colleagues conducted a study published in Diabetes, Obesity, and Metabolism in 2017 that showed that individuals who were taking metformin while taking a GLP-1 were more likely to have side effects, especially nausea and vomiting
Discovery and characterization of the incretin hormones Discovery and characterization of the incretin hormones Trust your gut
Paul Sarmiento , Senior Medical Director, Clinical Quality Since the first oral GLP-1 for weight loss was approved in late December 2025, commercials may have led people to believe all the barriers have been removed
Understanding how both incretin receptors work together The way that incretin receptors work together in the pancreas is not yet very clear
Additionally, there were more deaths in the Tirzepatide group than semaglutide (12 vs 1)
The rise of the incretin therapies for obesity has attracted tremendous interest, both from drug developers and prospective patients (consumers)
